Stocktoria
Lucid Diagnostics Inc. LUCD
Lucid Diagnostics Inc. (LUCD) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $4.7M at a -1232.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LUCD | Lucid Diagnostics Inc. | 3/9 | — | — | — |
| PSTV | PLUS THERAPEUTICS, INC. | 3/9 | — | — | — |
| TNON | Tenon Medical, Inc. | 4/9 | — | — | — |
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | 2/9 | — | — | — |
| OSRH | OSR Health, Inc. | — | 1.04 | — | — |
| USAQ | QHSLab, Inc. | 4/9 | -1.02 | — | — |
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
FAQ
Is LUCD financially healthy?
Lucid Diagnostics Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does LUCD pay a dividend?
No, Lucid Diagnostics Inc. does not currently pay a dividend.
How profitable is LUCD?
In FY2025, Lucid Diagnostics Inc. had a net margin of -1232.7% and a return on equity of -530.4%.
What is the analyst price target for LUCD?
The average Wall-Street price target for Lucid Diagnostics Inc. is $3.95, about 301.3% above the recent price, from 5 analysts.
Is LUCD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Lucid Diagnostics Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.